Skip to main content

Dr. Abderrazzak Merzouki

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Dr. Abderrazzak Merzouki

Sunshine Biopharma Inc. reported in an 8-K filed February 5, 2026 that Dr. Abderrazzak Merzouki resigned as chief operating officer, effective February 5, 2026. Sunshine Biopharma Inc. reported in an 8-K filed January 30, 2024 that Dr. Abderrazzak Merzouki was appointed Chief Science Officer, effective January 25, 2024. The proxy statement of Sunshine Biopharma Inc. reports total compensation of $260,000 for Dr. Abderrazzak Merzouki in fiscal 2023, including a base salary of $252,000. Disclosed compensation is on record for 3 fiscal years.

“On February 5, 2026, Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective immediately.”
Sunshine Biopharma Inc. Form 8-K, filed February 5, 2026 · Read the filing
“At the meeting the following persons were elected to the following positions: Dr. Abderrazzak Merzouki | Chief Science Officer”
Sunshine Biopharma Inc. Form 8-K, filed January 30, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Sunshine Biopharma Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Sunshine Biopharma Inc. (SBFM) $252,000 $260,000
2022 Sunshine Biopharma Inc. (SBFM) $240,000 $485,000
2021 Sunshine Biopharma Inc. (SBFM) $109,927 $415,927

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.